| Name of the antibody | Number of positive samples with citrate treatment only | % age of positive samples with citrate treatment only | Number of positive samples with citrate and Tris-EDTA treatment | % age of positive samples with citrate and Tris-EDTA treatment | Number of positive samples with citrate, Tris-EDTA and pepsin treatment | % age of positive samples with citrate, Tris-EDTA and pepsin treatment |
| VEGF-D | 3 | 6.67 | 33 | 73.33 | 0 | 0 |
| VEGFR-3 | 6 | 13.33 | 39 | 86.67 | 0 | 0 |
| Podoplanin | 10 | 22.22 | 40 | 88.89 | 0 | 0 |
| PROX 1 | 8 | 17.78 | 25 | 55.56 | 0 | 0 |
| LYVE-1 | 5 | 11.11 | 28 | 62.22 | 0 | 0 |
| Laminin | 0 | 0 | 0 | 0 | 39 | 86.67 |
| VEGFR-2 | 5 | 11.11 | 40 | 88.87 | 0 | 0 |
| VEGF-C | 0 | 0 | 0 | 0 | 0 | 0 |